Press release
Palmoplantar Keratoderma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc.
Palmoplantar Keratoderma Pipeline Analysis
DelveInsight's analysis indicates that over three key companies are actively engaged in developing more than three treatment therapies for Palmoplantar Keratoderma.
Palmoplantar Keratoderma Overview:
Palmoplantar keratoderma (PPK) refers to a group of skin conditions marked by thickened skin on the palms and soles. It can be acquired-often due to environmental or health-related factors-or inherited through genetic mutations that affect keratin, a key structural protein in the skin.
Common symptoms include widespread thickening of the skin (keratosis) on the palms and soles, often bordered by a red band. Additional thickened lesions may also appear on the backs of the hands and feet, as well as on the knees and elbows. Other frequent features include excessive sweating and thickened nails.
Treatment generally involves the use of topical keratolytic agents, such as salicylic acid and benzoic acid formulations, to help reduce skin thickening.
Request for a detailed insights report on Palmoplantar Keratoderma pipeline insights [https://www.delveinsight.com/report-store/palmoplantar-keratoderma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Palmoplantar Keratoderma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Palmoplantar Keratoderma Therapeutics Market.
Key Takeaways from the Palmoplantar Keratoderma Pipeline Report
*
DelveInsight's report on the Palmoplantar Keratoderma (PPK) pipeline highlights a promising and evolving therapeutic landscape, with over three active companies working on the development of more than three treatment candidates for PPK.
*
Key players such as Sol-Gel Technologies Ltd., Krystal Biotech Inc., and others are advancing novel therapies aimed at improving outcomes for patients with PPK. Among the promising candidates in development is SGT-210, along with additional compounds in various clinical stages.
*
A Phase 1b study investigating KM-001, a TRPV3 inhibitor, in patients with PPK-including those with Pachyonychia Congenita (PC) and Punctate Palmoplantar Keratoderma type 1 (PPPK1)-demonstrated favorable safety and preliminary effectiveness. Improvement in at least one clinical parameter (such as disease severity, pain, or itch) was observed in 86% of participants in Israel and 88% in the UK. Additionally, 47% of all patients improved in at least two areas, with six out of ten PC patients reporting pain relief.
*
In 2024, Sol-Gel Technologies launched a Phase 1 proof-of-concept study for SGT-210, focusing on its safety and effectiveness in treating PPK-an important milestone in developing targeted therapies for this condition.
*
A Phase 2 trial is currently underway to assess the safety and efficacy of Tapinarof, a naturally derived compound previously used in psoriasis treatment, in adults with PPK. This effort reflects a trend toward repurposing existing dermatological therapies for new indications.
*
Furthermore, in August 2024, the European Medicines Agency (EMA) granted orphan drug designation to a novel compound, (R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone, for the treatment of punctate palmoplantar keratoderma. This designation supports the development of therapies for rare and underserved conditions like PPK.
Palmoplantar Keratoderma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Palmoplantar Keratoderma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Palmoplantar Keratoderma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Palmoplantar Keratoderma market.
Download our free sample page report on Palmoplantar Keratoderma pipeline insights [https://www.delveinsight.com/sample-request/palmoplantar-keratoderma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Palmoplantar Keratoderma Emerging Drugs
*
SGT-210: Sol-Gel technologies Ltd.
Palmoplantar Keratoderma Companies
Around three or more major companies are actively working on developing treatments for Palmoplantar Keratoderma. Among them, Sol-Gel Technologies Ltd. leads with the most advanced drug candidate, which is currently in Phase I clinical trials.
DelveInsight's report covers around 3+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Palmoplantar Keratoderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Palmoplantar Keratoderma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Palmoplantar Keratoderma Therapies and Key Companies: Palmoplantar Keratoderma Clinical Trials and advancements [https://www.delveinsight.com/report-store/palmoplantar-keratoderma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Palmoplantar Keratoderma Pipeline Therapeutic Assessment
- Palmoplantar Keratoderma Assessment by Product Type
- Palmoplantar Keratoderma By Stage
- Palmoplantar Keratoderma Assessment by Route of Administration
- Palmoplantar Keratoderma Assessment by Molecule Type
Download Palmoplantar Keratoderma Sample report to know in detail about the Palmoplantar Keratoderma treatment market @ Palmoplantar Keratoderma Therapeutic Assessment [https://www.delveinsight.com/sample-request/palmoplantar-keratoderma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Palmoplantar Keratoderma Current Treatment Patterns
4. Palmoplantar Keratoderma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Palmoplantar Keratoderma Late-Stage Products (Phase-III)
7. Palmoplantar Keratoderma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Palmoplantar Keratoderma Discontinued Products
13. Palmoplantar Keratoderma Product Profiles
14. Palmoplantar Keratoderma Key Companies
15. Palmoplantar Keratoderma Key Products
16. Dormant and Discontinued Products
17. Palmoplantar Keratoderma Unmet Needs
18. Palmoplantar Keratoderma Future Perspectives
19. Palmoplantar Keratoderma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Palmoplantar Keratoderma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/palmoplantar-keratoderma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=palmoplantar-keratoderma-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-solgel-technologies-ltd-krystal-biotech-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Palmoplantar Keratoderma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc. here
News-ID: 4136025 • Views: …
More Releases from ABNewswire
Playground Play Equipment Innovation Sets New Benchmark for Safe, Engaging Space …
As schools, communities, and commercial venues worldwide continue to invest in healthier and more inclusive outdoor environments, playground play equipment [https://www.indooroutdoorplayground.com/what-makes-playground-play-equipment-truly-safe-and-engaging/] is entering a new era-one defined by higher safety standards, smarter design, and broader community engagement. Golden Times (Wenzhou Golden Times Amusement Toys CO., LTD.) today announced an expanded product and market strategy focused on delivering next-generation playground solutions that balance safety, durability, and creativity.
Industry expectations for playgrounds have…
Time.so Reports 300% Growth in Business Users
Time.so reports 300% growth in business users as global teams rely on its fast world clock, city times, time zones, and weather for planning.
Jan 31, 2026 - Time.so today announced a 300% increase in business users, reflecting rising demand for dependable time data across distributed teams, global customer support, and cross border operations.
The surge follows a clear shift in how companies schedule work. Meetings span continents. Deadlines move with daylight…
Shaun Savvy Helps Tuckaway Farm in Bentonville, Arkansas Sell Out Two CSA Season …
Buffalo-based SEO consultant Shaun Savvy partnered with Tuckaway Farm in Bentonville, Arkansas to help the farm sell out two consecutive CSA seasons, generating over $80,000 in revenue while spending less than $1,000 on paid advertising through a strategic blend of local SEO, high-intent content, and targeted social media campaigns.
Shaun Savvy, a Buffalo-based SEO and digital marketing consultant, announced a successful local marketing case study showcasing how Tuckaway Farm sold out…
Desert-Proven Skincare: How Corrective Skin LLC's Three-Decade Formula Testing C …
Corrective Skin LLC leverages the extreme conditions of the Utah desert as a rigorous testing environment for their professional-grade skincare line. With 30 years of formulation refinement in one of the country's harshest climates, the female-founded company offers growth factor treatments and advanced skincare that deliver results where other products fail.
The Utah desert presents one of the most demanding environments for skin health in North America, making it an ideal…
More Releases for Palmoplantar
Palmoplantar Keratoderma (PPK) market is expected to reach USD 2.4 billion by 20 …
Palmoplantar keratoderma (PPK) refers to a group of skin disorders characterized by thickened skin on the palms and soles due to abnormal keratinization. PPK can be inherited or acquired, with symptoms ranging from mild thickening to painful fissures that significantly impair quality of life. While most cases are rare, the burden on patients is substantial, often requiring lifelong management.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71429
Growing awareness of…
Palmoplantar Pustulosis Market is expected to reach USD 4.8 billion by 2034
Palmoplantar pustulosis (PPP) is a rare, chronic, and debilitating inflammatory skin disease characterized by recurring sterile pustules on the palms and soles. PPP significantly impairs quality of life due to pain, itching, and functional limitations. Traditionally managed with corticosteroids and systemic immunosuppressants, the disease remains difficult to treat, with high relapse rates and limited therapeutic options.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71387
In recent years, however, the market…
Strong Growth Ahead: Palmoplantar Pustulosis Market Size To Grow At Arecord 7.9% …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Big Is the Palmoplantar Pustulosis Market Size Expected to Be by 2034?
The market for palmoplantar pustulosis has seen significant expansion in the past few years. The market, which is set to progress from $1.93 billion in 2024 to $2.10 billion in 2025, is expected to experience a compound annual growth rate (CAGR)…
Palmoplantar Keratoderma Market Growth 2025: Trends, Consumer Demand, and Key Op …
The Latest research report on the Palmoplantar Keratoderma Market 2025 provides a comprehensive analysis of the current market landscape, with forecasts extending to 2032. This study combines qualitative and quantitative insights to highlight significant market developments, challenges, competitive dynamics, and potential opportunities and trends shaping the Palmoplantar Keratoderma Market. The report covers market size, recent trends, growth projections, market share, and development status. Additionally, it examines government policies, market dynamics,…
Strong Growth Ahead: Palmoplantar Pustulosis Market Size To Grow At Arecord 7.9% …
The Palmoplantar Pustulosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Palmoplantar Pustulosis Market Size Expected to Be by 2034?
In recent times, the market size for palmoplantar pustulosis has seen considerable growth. It's expected to rise from $1.93 billion in 2024…
Japan Palmoplantar Pustulosis (PPP) Market Size, Company Profiles and Key Figure …
Japan Palmoplantar Pustulosis (PPP) market analysis report encompasses many vital parameters about market analysis which can be used for the business. Analysis and estimation of important industry trends, market size, and market share are mentioned in this industry report. The report helps to measure and optimize each step in the lifecycle of industrial process including engagement, acquisition, retention, and monetization. Japan Palmoplantar Pustulosis (PPP) business research report is prepared by…
